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interactions and what amino acids? 
Mutagenesis of amino acids at the 
interface between PDZ and the pro-
tease domains revealed some tantaliz-
ing clues. Three amino acids (Lys243, 
Arg256, and Asp320) in the PDZ domain 
were found to be particularly impor-
tant, as their mutation led to drastically 
increased basal rate cleavage of RseA 
(Sohn et al., 2007). In addition, Arg178 
in the protease domain, which is highly 
conserved among DegS orthologs, 
was thought to be the key determinant 
in the allosteric switch from the inactive 
to active conformation.
These latest advances contribute 
to an improved model (Figure 1) and 
make quantitative understanding of 
the OMP stress response possible. 
For example, the moderate binding 
affinities between the OMP peptides 
and DegS likely ensure a threshold for 
detection of the stress response: only 
when there is an accumulation of the 
unfolded OMP proteins. In addition, 
the wide range of binding affinities for 
DegS—4.6 µM for the YYF sequence 
and 130 µM for the YAF sequence 
(Sohn et al., 2007)—may set a differ-
ent threshold for the accumulation of 
differing OMP proteins. It should be 
noted, however, that many unanswered 
questions remain. RseB, a periplasmic 
protein that binds to RseA, was shown 
to inhibit DegS-mediated cleavage of 
RseA in vitro regardless of the OMP 
peptides (Cezairliyan and Sauer, 2007). 
The molecular basis for this inhibition 
remains to be investigated. How DegS 
overcomes RseB-mediated inhibi-
tion of RseA during the OMP stress 
response remains unclear. Periplasmic 
proteolysis of RseA by DegS is merely 
a prerequisite for the second cleavage 
of RseA by the membrane-embedded 
metalloprotease YaeL—why this is the 
case remains unknown.
DegS is a representative member 
of a family of PDZ-containing serine 
proteases (Clausen et al., 2002). Does 
the allosteric mechanism observed 
for DegS apply to other family mem-
bers? After all, these proteases share 
conserved domain structures and 
sequences and form trimers in solu-
tion. Similar to DegS, deletion of the 
PDZ domain makes human HtrA2 (a 
DegS homolog) more active (Li et al., 
2002). Therefore, it is tempting to spec-
ulate that the mechanism of activation 
described by Sohn et al. might be gen-
erally applicable to other members of 
this family of proteases.
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An agent that blocks tumor angiogenesis, growth, and metastasis without affecting normal 
tissues—whether used alone or in combination with currently approved drugs—would 
change the way we treat cancer. In this issue, Fischer et al. (2007) offer compelling evidence 
that a monoclonal antibody against placental growth factor (PlGF), a member of the VEGF 
family, has such potential in mice.Vascular endothelial growth factor 
(VEGF) plays an indispensable role 
in the formation of new blood ves-
sels in both physiological and path-ological settings. The anti-VEGF 
monoclonal antibody bevacizumab 
(referred to henceforth as αVEGF), 
when used as the sole therapy in Cell 131, Novphase III clinical trials, has yet to 
produce improvements in overall 
survival rates for cancer patients. On 
the other hand, addition of αVEGF to ember 2, 2007 ©2007 Elsevier Inc. 443
Table 1. Effects of αVEGFR-2/sVEGFR-2 and αPlGF on Normal and  
Tumor Tissues
αVEGFR-2/sVEGFR-2 αPlGF
Inhibition of tumor growth
 VEGFRI-sensitive tumors + +
 VEGFRI-insensitive tumors − +
Pruning of tumor vessels + +
Induction of endothelial cell apoptosis + +
Inhibition of macrophage recruitment − +
Circulating monocyte count Increase Decrease
Inhibition of lymphangiogenesis +/? +
Induction of angiogenic rescue program + −
Enhanced chemotherapy efficacy + +
Toxicity
 Pruning of normal vessels + −
 Decreased body weight + −
 Proteinuria + −
 Increased risk of thrombosis + −
 Hypertension + −
 Embryonic development arrest + −
VEGF binds and activates VEGFR-1 as well as VEGFR-2. PlGF binds and signals only 
through VEGFR-1. VEGF, vascular endothelial growth factor; PlGF, placental growth 
factor; αVEGFR-2, anti-VEGF receptor 2 antibody; sVEGFR-2, soluble VEGF receptor 
2; αPlGF, anti-PlGF antibody; VEGFRI, VEGF receptor inhibitor.standard chemotherapy regimens 
can extend survival of patients with 
metastatic colorectal or lung cancer 
by 2 to 5 months with manageable 
toxicities. These results raise many 
critical questions (Jain et al., 2006). 
First, why is such a combination 
effective against some malignan-
cies, such as colorectal or lung can-
cer, and not against others, such as 
pancreatic cancer? Second, how 
can we extend survival beyond a 
few months in patients in which such 
a combination does work? Third, 
how can we minimize the adverse 
effects of blocking VEGF signaling? 
In this issue of Cell, Fischer, Car-
meliet, and colleagues (Fischer et 
al., 2007) offer a potential solution 
to these challenges in the form of a 
monoclonal antibody (αPlGF) that 
neutralizes murine placental growth 
factor (PlGF), a member of the VEGF 
family.
Only 300 papers have been pub-
lished on PlGF, which was cloned 
in 1991 (Maglione et al., 1991). In 
contrast, more than 21,000 papers 444 Cell 131, November 2, 2007 ©2007 Ehave been published on VEGF, 
which was cloned 2 years earlier, 
in 1989 (Dvorak, 2006; Ferrara et 
al., 2004). Human PlGF encodes 
four isoforms (PlGF-1 to PlGF-4), 
whereas mouse PlGF encodes 
a single isoform (PlGF-2). Unlike 
VEGF-deficient mice, which die dur-
ing embryogenesis, PlGF-deficient 
mice develop normally. In a series 
of elegant experiments, Carmeliet 
and his group previously showed 
that loss of PlGF impairs pathologi-
cal angiogenesis in adults, including 
new blood vessel formation asso-
ciated with tumors (Luttun et al., 
2002). They also demonstrated that 
murine PlGF amplifies VEGF sig-
naling in endothelial cells through 
VEGF receptor 1 (VEGFR-1) trans-
phosphorylation of VEGFR-2 and 
that recombinant PlGF treatment 
stimulates revascularization of isch-
emic tissues (Autiero et al., 2003; 
Carmeliet et al., 2001; Luttun et al., 
2002). Based on these seminal stud-
ies, Carmeliet and colleagues put 
forth the hypothesis that an αPlGF lsevier Inc.monoclonal antibody could serve as 
a safer antiangiogenic agent than 
an αVEGF monoclonal antibody 
and could perhaps substitute for 
or augment the effect of anti-VEGF 
therapy. As PlGF levels are known 
to increase in the circulation of can-
cer patients receiving anti-VEGF 
treatment (Batchelor et al., 2007; Xu 
and Jain, 2007), αPlGF could also 
counter this side effect of anti-VEGF 
therapy.
In this issue, Fischer et al. (2007) 
provide compelling evidence in sup-
port of this hypothesis (Table 1). The 
authors developed a specific block-
ing antibody against mouse PlGF-2 
with no crossreactivity against the 
human PlGFs. To test the function 
of this antibody, they used mouse 
melanoma, pancreatic carcinoma, 
colon carcinoma, and lymphoma 
cell lines, all of which express abun-
dant PlGF, and demonstrated that 
αPlGF inhibited tumor growth in 
both ectopic and orthotopic mouse 
tumor models. αPlGF also inhibited 
metastases of these tumors to the 
bile duct and lymph nodes as well as 
formation of ascites by an orthoto-
pic pancreatic tumor. Furthermore, 
αPlGF enhanced the efficacy of the 
chemotherapeutic agents cyclo-
phosphamide and gemcitabine in 
murine melanoma and pancreatic 
tumor models (Table 1).
One of the major problems in 
antiangiogenesis therapy is the 
propensity for malignant tumors to 
become resistant to treatments tar-
geted against individual angiogenic 
factors by switching to production 
of other angiogenic molecules. For 
example, in a clinical trial in rec-
tal cancer patients, plasma levels 
of both VEGF and PlGF increased 
after treatment with the αVEGF 
monoclonal antibody bevacizumab 
alone (Willett et al., 2005). The 
same phenomenon was observed 
in recurrent glioblastoma and in 
metastatic renal cell cancer patients 
receiving receptor tyrosine kinase 
inhibitors whose targets include 
the VEGFR-2 pathway (Batchelor et 
al., 2007; Motzer et al., 2006). Fis-
cher et al. (2007) hypothesized that 
this increase in VEGF and PlGF is 
secondary to hypoxia and necrosis 
caused by anti-VEGF treatments. 
Indeed, unlike αVEGFR-2 or soluble 
VEGFR-2 (sVEGFR-2), αPlGF treat-
ment did not cause severe hypoxia 
or necrosis or increases in plasma 
or tumor levels of VEGF and PlGF. 
On the other hand, αPlGF treatment 
enhanced the antitumor effects of 
αVEGFR-2 and sVEGFR-2. It would 
be worthwhile to test whether 
monoclonal antibodies that block 
both murine PlGF and VEGF would 
produce a similar outcome.
Another important issue is the 
toxicity of anti-VEGF agents. 
Although some side effects (such as 
hypertension) are often manageable 
with medication, rare but severe 
adverse effects have been reported, 
including thrombosis, bleeding, and 
gastrointestinal perforations (Ver-
heul and Pinedo, 2007). Most of 
these adverse effects are presum-
ably downstream effects of block-
ing VEGF signaling via VEGFR-2 in 
endothelial cells of normal tissues. 
Quiescent blood vessels lack VEG-
FR-1, and PlGF levels are negligible 
in normal tissues; thus, αPlGF, unlike 
αVEGFR-2, does not affect body 
weight or embryonic development. 
Treatment with αVEGFR-2, but not 
αPlGF, resulted in pruning of blood 
vessels in normal organs such as the 
thyroid gland. However, the com-
bination of αPlGF and αVEGFR-2, 
while boosting therapeutic efficacy, 
did not further enhance the prun-
ing of normal blood vessels. Thus, 
αPlGF appears to be a safer anti-
angiogenic agent than αVEGFR-2, 
opening up the possibility of its use 
in treating pediatric or pregnant 
cancer patients.
Like any groundbreaking work, 
this study raises many questions. 
The most important one from a 
translational point of view is the 
prevalence of PlGF expression in 
human tumors. VEGF levels are 
elevated in most human tumors and 
often correlate with prognosis. In 
contrast, elevated PlGF expression 
is restricted to a subset of tumors 
such as breast and gastric carcino-mas (Fischer et al., 2007). The low 
expression of PlGF in some tumors 
could be due to the aberrant methy-
lation of the PlGF promoter (Xu and 
Jain, 2007). On the other hand, PlGF 
is expressed by endothelial cells, 
leukocytes, and other stromal cells. 
Fischer et al. (2007) chose tumor 
cell lines that abundantly express 
PlGF, and so the antitumor effect of 
αPlGF could have resulted from tar-
geting both malignant and stromal 
cells. What is the effect of αPlGF 
in human tumor xenografts in mice 
or in murine tumors in which PlGF 
expression is low in cancer cells?
Fischer et al. (2007) have care-
fully dissected mechanisms by 
which αPlGF exerts its antiangio-
genic and antitumor effects. They 
demonstrate that αPlGF blocks 
accumulation of macrophages in 
tumors and then suggest how this 
mechanism makes αPlGF a potent 
blocker of lymphangiogenesis and 
lymphatic metastasis. They attri-
bute the inability of αVEGFR-2 to 
inhibit macrophage infiltration as 
contributing to the resistance of 
these tumors to αVEGFR-2 and thus 
propose that αPlGF treatment could 
be particularly valuable when com-
bined with VEGFR-2 blockade.
Another question that needs to be 
addressed is how αPlGF enhances 
the outcome of chemotherapy. Does 
αPlGF normalize abnormal blood 
vessel formation and the microenvi-
ronment of tumors, resulting in better 
delivery and efficacy of chemothera-
peutics? Does αPlGF target cancer 
and host cells that are dependent 
on VEGFR-1 signaling for survival? 
Does αPlGF block the recruitment 
of vascular modifying cells that 
express VEGFR-1? How does αPlGF 
affect the metastatic seeding of can-
cer cells at other sites in the body? 
Given that αVEGF is efficacious and 
approved for use with chemotherapy 
in two major metastatic diseases, 
scheduling αPlGF with αVEGF and/
or chemotherapy is likely to be the 
most important challenge in trans-
lating these findings to the clinic. In 
the meantime, αPlGF offers the pos-Cell 131, Nsibility of an antiangiogenic agent 
that is potent and has little toxic-
ity when combined with anti-VEGF 
strategies. Let us welcome this new 
kid on the antiangiogenic block and 
hope that it offers new opportunities 
for treating many different types of 
cancers.
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